Ladenburg Thalmann Recommends Acquiring Shares Of Tenax Therapeutics At Current Prices As They Believe The Possible Risk/Reward Of A Positive Phase 2 Outcome Could Offer A Strong Risk/Reward Profile From Current Valuation